Chiasma
is engaged in developing and commercializing novel oral formulations of therapies to treat chronic diseases... Read moreChiasma
is engaged in developing and commercializing novel oral formulations of therapies to treat chronic diseases... Read more
News
Aug 05, 2021
centralcharts
Press Release: Chiasma : Amryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
Jul 02, 2021
Benzinga
Chiasma: INVESTIGATION ALERT: Halper Sadeh LLP Investigates HGV, CHMA, ONDS, BOCH; Shareholders are Encouraged to Contact the Firm
Jun 29, 2021
Benzinga
Chiasma: Chiasma Files Mycapssa European Application For Acromegaly
Jun 28, 2021
BioSpace
Chiasma: Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
Jun 22, 2021
MarketScreener
Chiasma: Chiasma : Expiration of HSR Waiting Period (Form 8-K)
Jun 15, 2021
FE Investegate
Chiasma: Amryt Pharma plc : Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
May 28, 2021
Benzinga
Chiasma: Chiasma's Mycapssa Associated With Positive Patient-Reported Outcomes In Acromegaly Patients
May 20, 2021
StreetInsider
Press Release: Chiasma : Chiasma to Present Encore and New Data from MPOWERED Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences
May 13, 2021
Business Wire
Press Release: Chiasma : Acentrus Specialty Contracts with Chiasma to Bring MYCAPSSA (octreotide) to Health Systems and Hospitals in the Acentrus Network
May 08, 2021
Virtual-Strategy Magazine
Chiasma: SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chiasma, Inc. - CHMA
Chiasma Competitors
1
2
3
4
5
6
7
8
9
10